Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11201553 | 0.82 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL7200830 | 0.82 | GRIN1 (0.33) | GRIN1GRIN2A | |
| SCHEMBL7199174 | 0.82 | GRIN1 (0.36) | GRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL10549743 | 0.80 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL11196121 | 0.79 | CYP19A1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL11216551 | 0.77 | GRIN1 (0.31) | GRIN1GRIN2A | |
| SCHEMBL31488213 | 0.76 | LMNA (0.34) | GRIN1GRIN2A | |
| SCHEMBL11199937 | 0.76 | CYP19A1 (0.40) | GRIN1GRIN2A | |
| SCHEMBL27649467 | 0.72 | GAA (0.32) | — | |
| SCHEMBL8259945 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4743691-A | INHIBITORS OF ORNITHINE DECARBOXYLASE | MERRELL DOW FRANCE ET CIE (FR) | 1988-05-10 | — | — | US | claimed |
| EP-1421058-B1 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | SKINMEDICA INC (US) | 2010-05-05 | — | — | EP | disclosed |
| CN-1447686-A | D-enantiomers of DFMO and methods of use thereof | ILEX ONCOLOGY INC (US) | 2003-10-08 | — | — | CN | disclosed |
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
| US-4866206-A | INHIBITORS OF ORNITHINE DECARBOXYLASE | MERRELL DOW FRANCE ET CIE (FR) | 1989-09-12 | — | — | US | disclosed |
| US-4743691-A | INHIBITORS OF ORNITHINE DECARBOXYLASE | MERRELL DOW FRANCE ET CIE (FR) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | GRIN1 3533/4885GRIN2A 4482/4885OR51E2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.